The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Neo-AEGIS: preliminary results of the Phase III RCT of CROSS versus perioperative chemotherapy
John V. Reynolds, MD, St. James’s Hospital and Trinity College Dublin, Dublin, Ireland, discusses findings from the Neo-AEGIS study (NCT01726452), a Phase III neoadjuvant trial in adenocarcinoma of the esophagus and esophago-gastric junction cancer evaluating CROSS verses perioperative chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
